Kitov Pharma

Purple Biotech Ltd. is a development stage pharmaceutical company, which engages in drug development. It operates through two segments: Oncology, and Pain & Hypertension. The Oncology segment includes NT219, a therapeutic candidate which is a small molecule that targets two signal transduction pathways which are involved in the development of cancer drug resistance mechanisms, and which is currently in the late pre-clinical stage of development. The Pain & Hypertension segment includes Consensi, a combination drug for the simultaneous treatment of two clinical conditions, pain caused by osteoarthritis and hypertension (high blood pressure), which can be pre-existing or caused by the treatment for osteoarthritis. The company was founded by John Paul Waymack on August 12, 1968 and is headquartered in Rehovot, Israel.

Purple Biotech

REHOVOT, Israel, Jan. 18, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech”) (NASDAQ/TASE: PPBT), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced that the Purple Biotech management team will present a corporate overview at the B. Riley Oncology Investor Conference, being held virtually January 20-21, 2021.

Purple Biotech to Present at the B. Riley Oncology Investor Conference

New Name Reflects Company's Evolution to Advancing First-in-Class Oncology Therapies

Kitov Announces Name Change to Purple Biotech Ltd.

TEL AVIV, Israel, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced that management will present at the H.C. Wainwright 6th Annual Israel Conference and will participate in one-on-one meetings at the Jefferies Virtual London Healthcare Conference.

Kitov Pharma to Participate in November Investor Conferences

The new cohort will explore the combination of CM24, Opdivo (“nivolumab”) and Abraxane (“albumin-bound paclitaxel; nab-paclitaxel”) in patients with pancreatic cancer The new cohort will explore the combination of CM24, Opdivo (“nivolumab”) and Abraxane (“albumin-bound paclitaxel; nab-paclitaxel”) in patients with pancreatic cancer

Kitov Expands Planned Phase 1/2 Clinical Trial of CM24 in Non-Small Cell Lung Cancer with New Cohort to Evaluate CM24 in Patients with Pancreatic Cancer Conducted with Bristol Myers Squibb

Patent covers NT219's combinations with multiple 2nd and 3rd generation EGFR inhibitors, including osimertinib (TAGRISSO®)

Kitov Pharma Receives Notice of Allowance for a U.S. Patent Covering its Anti-Cancer Drug Candidate, NT219

Data Further Support Potential of NT219 to Overcome Cancer Drug Resistance

New Mechanism of Action Data for NT219 Presented at Epigenetics and Metabolism AACR Special Virtual Conference

Top Line Results from First Part of the Study Expected in Second Half of 2021 Top Line Results from First Part of the Study Expected in Second Half of 2021

Kitov Announces Dosing of First Patient in Phase 1/2 Clinical Trial of NT219 in Advanced Cancer Patients

Kitov’s patent coverage for CM24 and NT219 now extends to the U.S., EU, China, and multiple ROW countries

Kitov Pharma Receives Notice of Intention to Grant Two Patents in China Covering Company’s Lead Oncology Assets, CM24 and NT219

TEL AVIV, Israel, Aug.  12, 2020  (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, announced today that the Company will change the ratio of its American Depositary Shares (ADSs) to ordinary shares from one (1) ADS representing one (1) ordinary shares to a new ratio of one (1) ADS representing ten (10) ordinary shares. The ratio change will be effective at the beginning of trading on August 21, 2020. The primary purpose of the ADS ratio change is to enable the Company to regain compliance with the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market. 

Kitov Pharma Announces ADS Ratio Change

TEL AVIV, Israel, Aug.  11, 2020  (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today provided a corporate update and announced financial results for the six months ended June 30, 2020.

Kitov Pharma Provides Corporate Update and Reports First Half 2020 Financial Results

Is  (KTOV) Outperforming Other Medical Stocks This Year?

Is Kitov Pharmaceuticals Holdings (KTOV) Outperforming Other Medical Stocks This Year?

Company Evaluating NT219 as Monotherapy Treatment of Advanced Solid Tumors and in Combination with Cetuximab for the Treatment of Recurrent and/or Metastatic Solid Tumors and Head and Neck Cancer

Kitov Announces Initiation of Phase 1/2 Clinical Trial of NT219 in Advanced Cancer Patients

Patent coverage for CM24 now extends to the U.S. and the EU

Kitov Pharma Receives Notice of Intention to Grant a European Patent Covering CM24, its anti-CEACAM1 Antibody

Ties With Merck Could Explain Kitov's Market Interest

TEL AVIV, July 02, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, is pleased to provide the following letter to shareholders from its Chief Executive Officer, Isaac Israel.

Kitov Pharma Issues CEO Shareholder Letter Providing Business Update

TEL-AVIV, Israel, June  25, 2020  (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced the closing of its previously announced registered direct offering of 38,888,892 of the Company’s ordinary shares represented by American Depositary Shares (ADSs) and warrants to purchase up to an aggregate of 19,444,446 ADSs, at a combined purchase price of $0.90 per ADS and associated warrant to purchase 0.5 of an ADS for aggregate gross proceeds of approximately $35.0 million. Each ADS represents one ordinary share, no par value, of Kitov.  The warrants have an exercise price of $0.90 per ADS and are exercisable at any time upon issuance and expire five years from the date of issuance.

Kitov Closes $35.0 Million Registered Direct Offering

TEL-AVIV, Israel, June  23, 2020  (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced that it has entered into definitive agreements with several healthcare-focused institutional investors for the purchase and sale of 38,888,892 of the Company’s ordinary shares represented by American Depositary Shares (ADSs) and warrants to purchase up to an aggregate of 19,444,446 ADSs, at a combined purchase price of $0.90 per ADS and associated warrant, in a registered direct offering, for aggregate gross proceeds of approximately $35.0 million. Each ADS represents one ordinary share, no par value, of Kitov. The offering is expected to close on or about June 25, 2020, subject to satisfaction of customary closing conditions.

Kitov Announces $35.0 Million Registered Direct Offering

Company to Evaluate NT219 as Monotherapy Treatment of Advanced Solid Tumors and in Combination with Cetuximab for Treatment of Recurrent or Metastatic Solid Tumors and Head and Neck Cancer in a Phase 1/2 Trial

Kitov Announces U.S. FDA Acceptance of Investigational New Drug Application to Conduct Phase 1/2 Clinical Trial of NT219 in Multiple Types of Advanced Cancer Patients

TEL AVIV, Israel, May  20, 2020  (GLOBE NEWSWIRE) --  Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced the U.S. commercial launch of Consensi™, a fixed-dose combination of celecoxib and amlodipine besylate, designed for the simultaneous treatment of hypertension and osteoarthritis pain. Consensi™ is being sold in the U.S. by Burke Therapeutics, the marketing partner of Kitov’s U.S. distributor, Coeptis Pharmaceuticals.

Kitov Announces U.S. Commercial Launch of Consensi™

Company Expects to Initiate Phase 1/2 Trial of NT-219 as Monotherapy Treatment of Advanced Solid Tumors and in Combination with cetuximab for Treatment of Recurrent or Metastatic Solid Tumors and Head and Neck Cancer

Kitov to Present Preclinical Data on NT219 at American Association of Cancer Research Virtual Annual Meeting II

Company Expects to Initiate Phase 1/2 Clinical trial, in Collaboration with Bristol Myers Squibb, with CM-24 in Combination with nivolumab (Opdivo®) in Second Half of 2020

Kitov to Present Phase 1 Data on CM-24 in Patients with Advanced Cancer at American Society of Clinical Oncology 2020 Virtual Scientific Program

Tufin Software Technologies Ltd

Tufin Software Technologies Ltd. (TUFN) CEO Ruvi Kitov on Q1 2020 Results - Earnings Call Transcript

TEL-AVIV, Israel, May  08, 2020  (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced the closing of its previously announced registered direct offering of 25,000,002 of the Company’s ordinary shares represented by American Depositary Shares (ADSs), at a purchase price of $0.40 per ADS, in a registered direct offering, for aggregate gross proceeds of approximately $10 million.

Kitov Closes $10 Million Registered Direct Offering

TEL-AVIV, Israel, April  20, 2020  (GLOBE NEWSWIRE) --  Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced a transaction resulting in expected gross cash proceeds to Kitov of approximately $6.5 million, prior to deducting placement agent fees and estimated offering expenses, through the exercise of existing warrants by multiple holders to purchase 20.0 million  of the Company’s American Depositary Shares (“ADSs”) at an exercise price of $0.325 per share.  The ADSs issued upon exercise of the warrants are registered pursuant to Kitov’s registration statement on Form F-1 (File No. 333-235729), as amended, relating to such ADSs, which registration statement was declared effective by the Securities and Exchange Commission (SEC) on March 11, 2020 (the “Registration Statement”).  

Kitov Pharma Ltd. Announces Cash Proceeds of $6.5 Million from Exercise of Warrants

TEL AVIV, Israel, March  12, 2020  (GLOBE NEWSWIRE) --  Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today provided an update on the planned U.S. commercial launch of Consensi™, a fixed-dose combination of celecoxib, and amlodipine besylate, designed for the simultaneous treatment of osteoarthritis pain and hypertension, that was approved for marketing by the U.S. Food & Drug Administration. The Company’s manufacturing partner is completing the packaging, release and shipment of Consensi™ to Kitov’s marketing partners, that is expected to begin selling Consensi™ in the U.S. in May 2020.

News for Kitov Pharma Stock (KTOV)